Pipeline

August 20, 2018

Company	Drug/Device	Medical Condition	Status
Amicus Therapeutics	Galafold (migalastat)	Fabry disease	Approval granted by the FDA
Arbutus Biopharma Coporation and Alnylam Pharmaceuticals, Inc.	ONPATTRO (patisiran)	Hereditary transthyretin amyloidosis	Approval granted by the FDA
Ivantis, Inc.	Hydrus® Microstent, a microinvasive glaucoma surgery (MIGS) device	Mild to moderate primary open-angle glaucoma in conjunction with cataract surgery	Approval granted by FDA
Genentech	Xlair® (omalizumab)	Prevention of severe allergic reactions following accidental exposure to foods in people with allergies	Breakthrough Therapy Designation granted by the FDA
Samsung Bioepis, Co., Ltd.	SB26 ulinastatin-Fc (UTI-Fc) fusion protein	Severe acute pancreatitis	Phase I trial set to begin
Sesen Bio, Inc.	Vicinium™	Non-muscle invasive bladder cancer (NMIBC)	Granted Fast Track Designation by the FDA
BeiGene Ltd.	Tislelizumab, an investigational anti-PD-1 antibody, combined with chemotherapy	Potential first-line treatment for patients with Stage IIIB or IV squamous non-small cell lung cancer (NSCLC)	Phase III clinical trial initiated
Eiger BioPharmaceuticals, Inc.	Avexitide (formerly exendin 9-39)	Post-bariatric surgical patients who experience post-bariatric hypoglycemia (PBH)	Completion of enrollment in Phase II clinical trial
Izana Bioscience	Namilumab	Ankylosing spondylitis	Phase II proof-of-concept clinical trial initiated
Rafael Pharmaceuticals, Inc.	CPI-613 in combination with bendamustine	Relapsed or refractory T-Cell Lymphoma	Activation of a second clinical trial site for the Phase I study
Endomag	Magtrace, the first non-radioactive, dual-tracer	Lymphatic mapping in patients with breast cancer undergoing a mastectomy	Granted premarket approval granted by the FDA
Cannabics Pharmaceuticals, Inc.	Cannabics SR 5mg, daily for 3 months	Advanced Cancer and Cancer Anorexia Cachexia Syndrome (CACS)	Conclusion of trial announced; officials results are being evaluated
OrthoTrophix, Inc.	TPX-100	Osteoarthritis	Phase II trial results: improvements in function and cartilage in 55 percent of TPX-100 treated knees
Entasis Therapeutics	ETX2514SUL	Complicated urinary tract infections, including acute pyelonephritis (kidney infection) in adults	Positive topline results from Phase II trial
Realm Therapeutics	PR022	Atopic dermatitis	Phase II trial failed to reach endpoint goals
INOVA Diagnostics, Inc.	QUANTA Flash® HMGCR	Aids in the diagnosis of idiopathic inflammatory myopathy (IIM), a group of conditions that affect the skeletal muscles	Received FDA clearance